芩珠凉血合剂治疗亚急性湿疹的随机对照研究

Efficacy of Qinzhu Liangxue decoction on subacute eczema treatment

目的观察芩珠凉血合剂治疗亚急性湿疹的临床疗效及安全性。方法 55例亚急性湿疹患者随机分为2组。治疗组30例,予芩珠凉血合剂,一日2次,每次30 ml,饭后温服;对照组25例,予咪唑斯汀缓释片,一日1次,每次10 mg,均治疗4周。依据用药前后湿疹面积和严重程度评分(EASI)、皮肤病生活质量指标调查表评分(DLQI)评价治疗后效果,同时观察不良反应。结果与治疗前相比,两组治疗后EASI和DLQI评分均降低,且差异具有统计学意义(P<0.05)。两组在改善EASI评分方面疗效相当(P>0.05),但治疗组治疗前后DLQI评分差值较对照组更大(P<0.05)。治疗组总有效率为86.67%,对照组有效率为84.00%,两组差异无统计学意义(P>0.05)。治疗组患者在服药期间仅1例出现轻度胃部不适。结论芩珠凉血合剂治疗亚急性湿疹疗效确切,无明显不良反应,值得临床推广应用。

Objective To observe the clinical effect and safety of Qinzhu Liangxue decoction on subacute eczema. Methods A total of 55 cases of subacute eczema were randomly divided into two groups： 30 cases in treatment group and 25 cases in control group. The patients in treatment group were treated with Qinzhu Liangxue decoction, twice a day, each time 30 ml. The patients in the control group were treated with mizolastine sustained-release tablets, 10 mg once a day. The treatment for both groups was for 4 weeks. The eczema area and severity index（EASI） and the dermatology quality of life index（DLQI） before and after treatment were evaluated, and the effect of treatment and adverse reactions were observed. Results Compared with before treatment, DLQI and EASI of the two groups after treatment were reduced, and the difference was statistically significant（P〈0.05）. The two groups had equivalent effect in improving the EASI score（P〉0.05）, the DLQI difference value of treatment group was greater than that of control group after treatment（P〈0.05）. The total effective rate of treatment group was 86.67%, and the control group was 84.00%, and there was no significant difference between two groups（P〉0.05）. In the treatment group, only one patient suffered mild stomach discomfort during the period of taking medicine. Conclusion Qinzhu Liangxue decoction proves as an effective and safe method to treat subacute eczema.